Not available in the U.S.
Roxadustat
EVRENZO
What it isAn oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that stimulates endogenous erythropoietin and improves iron handling.
Why this oneIt treats anemia of chronic kidney disease and is approved in China, Japan, and Europe, though the FDA declined US approval.
What limits itSignals of increased thromboembolic and cardiovascular events led an FDA advisory committee to recommend against approval for US CKD anemia.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning (not FDA-approved; US approval was declined in 2021 over thrombotic/cardiovascular safety concerns).
Classes and tags
Clinical profile
Mechanism of action: Roxadustat ballicule
